US EditionSettlement Administrator Angeion Group Issues a Reminder Regarding a Proposed Settlement In Calchi v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC Class Action
- A federal court authorized a notice about a class action settlement involving Haleon and Robitussin on April 11, 2025.
- Plaintiffs Nancy Galchi and Stacey Papalia claimed Haleon deceptively marketed Robitussin products as "Non-Drowsy" despite containing dextromethorphan .
- Haleon, formerly GlaxoSmithKline, agreed to settle the lawsuit, establishing a $4.5 million fund for eligible purchasers and ceasing "Non-Drowsy" labeling.
- The settlement fund covers settlement administration expenses, capped at $550,000, attorney fees up to $1.5 million, and $2,000 service awards per representative.
- A Final Approval Hearing will occur on June 30, 2025, but class members must submit claim forms by May 12, 2025, or exclude themselves by that date.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
All
Left
Center
11
Right
1
Bennington Banner+19 Reposted by 19 other sources
Settlement Administrator Angeion Group Issues a Reminder Regarding a Proposed Settlement In Calchi v. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC Class Action
If you bought certain Robitussin products between February 16, 2016, and January 21, 2025, you may be eligible to receive a payment in this class action settlement.
Coverage Details
Total News Sources20
Leaning Left0Leaning Right1Center11Last UpdatedBias Distribution92% Center
Bias Distribution
- 92% of the sources are Center
92% Center
C 92%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
